Late - postmenopausal ( > or = 5 years from menopause ) women with lumbar spine ( LS ) BMD T-score between -1 and -2.5 and the presence of > or = 1 additional risk factor for osteo - porosis or proximal femur ( Fern ) BMD T-score < or = -1 were randomized to receive risedronate 5 mg ( n = 114 ) or placebo ( n = 57 ) PO QD for 24 months .
